← Leaderboards
David R Spriggs
Sloan-Kettering Institute For Cancer Res
$13,987,182
Attributed
$14,955,461
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$45,845,717 · 16
By mechanism
P01$32,291,478 · 9
P50$5,203,085 · 3
U01$4,419,379 · 1
K12$1,452,418 · 1
K24$1,284,015 · 1
R01$1,195,342 · 1
Top collaborators
- Paul J Sabbatini5 shared
- Renier Joseph Brentjens3 shared
- Simon N Powell3 shared
- Alan David D'Andrea2 shared
- Ursula Anne Matulonis2 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Joseph Rocco Bertino$26,398,552
- Michel Sadelain$9,562,550
- Tanya M Trippett$245,646
- Nai-Kong V Cheung$9,578,208
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsClinical ResearchClinical TrialsMalignant Neoplasm Of OvaryPathway InteractionsMalignant NeoplasmsBaseMemorial Sloan-Kettering Cancer CenterImmunologicsNeoplasm /Cancer ChemotherapyHuman SubjectImmunotherapeutic AgentDrug ResistanceProteinsTranslational ResearchPaclitaxelResearch PersonnelVaccine DevelopmentAntibodiesLaboratoriesCa-125 AntigenHuman Therapy EvaluationFundingMutation
Grant awards (81)
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,264,107
P50 · FY2021 · CA
Career Enhancement Program (CEP)$133,063
P50 · FY2021 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,483,069
P50 · FY2020 · CA
Career Enhancement Program (CEP)$99,403
P50 · FY2020 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$2,002,763
P01 · FY2019 · CA
MUC16 Antibody Based Strategies for Imaging and Therapy$721,721
P01 · FY2019 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$163,445
P01 · FY2019 · CA
Adminstrative Core$103,108
P01 · FY2019 · CA · contact PI
Adminstrative Core$27,241
P01 · FY2019 · CA · contact PI
MUC16 Antibody Based Strategies for Imaging and Therapy$27,241
P01 · FY2019 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$2,033,832
P01 · FY2018 · CA
MUC16 Antibody Based Strategies for Imaging and Therapy$729,636
P01 · FY2018 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$168,500
P01 · FY2018 · CA
Adminstrative Core$104,237
P01 · FY2018 · CA · contact PI
Adminstrative Core$28,084
P01 · FY2018 · CA · contact PI
MUC16 Antibody Based Strategies for Imaging and Therapy$28,083
P01 · FY2018 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$2,033,832
P01 · FY2017 · CA
MSK Paul Calabresi Career Development Award for Clinical Oncology$761,904
K12 · FY2017 · CA
MUC16 Antibody Based Strategies for Imaging and Therapy$729,636
P01 · FY2017 · CA · contact PI
Adminstrative Core$104,237
P01 · FY2017 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$2,033,832
P01 · FY2016 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$636,514
K12 · FY2016 · CA
MUC16 Antibody Based Strategies for Imaging and Therapy$573,457
P01 · FY2016 · CA · contact PI
Adminstrative Core$81,926
P01 · FY2016 · CA · contact PI
Immunologic Approaches to Ovarian Cancer$2,052,807
P01 · FY2015 · CA · contact PI
MUC16 Antibody Based Strategies for Imaging and Therapy$580,100
P01 · FY2015 · CA · contact PI
Adminstrative Core$82,874
P01 · FY2015 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$54,000
K12 · FY2015 · CA
Career Development Program$43,251
P50 · FY2014 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$228,694
U01 · FY2013 · CA · contact PI
Career Development Program$43,759
P50 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$245,639
U01 · FY2012 · CA · contact PI
Career Development Program$46,673
P50 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$248,319
U01 · FY2011 · CA · contact PI
Career Development Program$44,215
P50 · FY2011 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$258,850
U01 · FY2010 · CA · contact PI
Clinical Investigator Development in Solid Tumor Oncology$153,090
K24 · FY2010 · CA · contact PI
Career Development Program$45,545
P50 · FY2010 · CA · contact PI
Epithelial Ovarian Cancer Program Project$2,085,988
P01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$717,824
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$256,656
U01 · FY2009 · CA · contact PI
Novel Strategy for the Re-Induction & Consolidation of Remission in Ovary Cancer$236,234
P01 · FY2009 · CA · contact PI
Clinical Investigator Development in Solid Tumor Oncology$153,090
K24 · FY2009 · CA · contact PI
Epithelial Ovarian Cancer Program Project$2,037,296
P01 · FY2008 · CA · contact PI
Novel Strategy for the Re-Induction & Consolidation of Remission in Ovary Cancer$231,061
P01 · FY2008 · CA · contact PI
Clinical Investigator Development in Solid Tumor Oncology$153,090
K24 · FY2008 · CA · contact PI
Epithelial Ovarian Cancer Program Project$2,029,433
P01 · FY2007 · CA · contact PI
Novel Strategy for the Re-Induction & Consolidation of Remission in Ovary Cancer$230,500
P01 · FY2007 · CA · contact PI
Clinical Investigator Development in Solid Tumor Oncology$153,090
K24 · FY2007 · CA · contact PI
Epithelial Ovarian Cancer Program Project$2,057,491
P01 · FY2006 · CA · contact PI
Clinical Investigator Development in Solid Tumor Oncology$151,487
K24 · FY2006 · CA · contact PI
Novel Strategy for Clinical Remission in Ovarian Cancer$105,761
P01 · FY2006 · CA · contact PI
Epithelial Ovarian Cancer Program Project$1,863,957
P01 · FY2005 · CA
CANCER CHEMOTHERAPY PROGRAM PROJECT$1,667,550
P01 · FY2005 · CA
Phase I Clinical Trials of Novel Agents$407,039
U01 · FY2005 · CA
Novel Strategy for Clinical Remission in Ovarian Cancer$102,816
P01 · FY2005 · CA
EPITHELIAL OVARIAN CANCER PROGRAM PROJECT$427,461
P01 · FY2004 · CA
Phase I Clinical Trials of Novel Agents$388,330
U01 · FY2004 · CA
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER$249,023
R01 · FY2004 · CA
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT$103,983
K24 · FY2004 · CA
Phase I Clinical Trials of Novel Agents$383,985
U01 · FY2003 · CA
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER$243,900
R01 · FY2003 · CA
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT$103,744
K24 · FY2003 · CA
EPITHELIAL OVARIAN CANCER PROGRAM PROJECT$1,781,716
P01 · FY2002 · CA
PHASE I STUDIES OF ANTICANCER AGENTS$449,651
U01 · FY2002 · CA
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER$238,922
R01 · FY2002 · CA
DEVELOPMENTAL CHEMOTHERAPY$188,635
P01 · FY2002 · CA
CORE--PHARMACOLOGY$188,635
P01 · FY2002 · CA
CORE--BIOSTATISTICS$188,635
P01 · FY2002 · CA
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT$103,513
K24 · FY2002 · CA
EPITHELIAL OVARIAN CANCER PROGRAM PROJECT$1,703,177
P01 · FY2001 · CA
PHASE I STUDIES OF ANTICANCER AGENTS$424,732
U01 · FY2001 · CA
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER$234,092
R01 · FY2001 · CA
DEVELOPMENTAL CHEMOTHERAPY$188,635
P01 · FY2001 · CA
CORE--PHARMACOLOGY$188,635
P01 · FY2001 · CA
CORE--BIOSTATISTICS$188,635
P01 · FY2001 · CA
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT$103,290
K24 · FY2001 · CA
PHASE I STUDIES OF ANTICANCER AGENTS$409,660
U01 · FY2000 · CA
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER$229,405
R01 · FY2000 · CA
DEVELOPMENTAL CHEMOTHERAPY$188,635
P01 · FY2000 · CA
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT$105,638
K24 · FY2000 · CA